About: The effect of delaying transperineal fusion biopsy of the prostate for patients with suspicious MRI findings

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The effect of delaying transperineal fusion biopsy of the prostate for patients with suspicious MRI findings—Implications for the COVID-19 era Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The effect of delaying transperineal fusion biopsy of the prostate for patients with suspicious MRI findings—Implications for the COVID-19 era
Creator	Barnes, Sophie Dekalo, Snir Gitstein, Gilad Keren-Paz, Gal Mabjeesh, Nicola Mano, Roy Marom, Ron Matzkin, Haim Savin, Ziv Yossepowitch, Ofer
Source	Elsevier; Medline; PMC
abstract	OBJECTIVE: Image guided biopsies are an integral part of prostate cancer evaluation. The effect of delaying biopsies of suspicious prostate mpMRI lesions is uncertain and clinically relevant during the COVID-19 crisis. We evaluated the association between biopsy delay time and pathologic findings on subsequent prostate biopsy. MATERIALS AND METHODS: After obtaining IRB approval we reviewed the medical records of 214 patients who underwent image-guided transperineal fusion biopsy of the prostate biopsy between 2017 and 2019. Study outcomes included clinically significant (ISUP grade group ≥2) and any prostate cancer on biopsy. Logistic regression was used to evaluate the association between biopsy delay time and outcomes while adjusting for known predictors of cancer on biopsy. RESULTS: The study cohort included 195 men with a median age of 68. Median delay between mpMRI and biopsy was 5 months, and 90% of patients had a ≤8 months delay. A significant association was found between PI-RADS 5 lesions and no previous biopsies and shorter delay time. Delay time was not associated with clinically significant or any cancer on biopsy. A higher risk of significant cancer was associated with older age (P = 0.008), higher PSA (0.003), smaller prostate volume (<0.001), no previous biopsy (0.012) and PI-RADS 5 lesions (0.015). CONCLUSIONS: Our findings suggest that under current practice, where men with PI-RADS 5 lesions and no previous biopsies undergo earlier evaluation, a delay of up to 8 months between imaging and biopsy does not affect biopsy findings. In the current COVID-19 crisis, selectively delaying image-guided prostate biopsies is unlikely to result in a higher rate of significant cancer.
has issue date	2020-08-07(xsd:dateTime)
bibo:doi	10.1016/j.urolonc.2020.07.009
bibo:pmid	32778478
has license	no-cc
sha1sum (hex)	5f7909edfb0ee7555009cda926d7341eece2045f
schema:url	https://doi.org/10.1016/j.urolonc.2020.07.009
resource representing a document's title	The effect of delaying transperineal fusion biopsy of the prostate for patients with suspicious MRI findings—Implications for the COVID-19 era
has PubMed Central identifier	PMC7413128
has PubMed identifier	32778478
schema:publication	Urol Oncol
resource representing a document's body	covid:5f7909edfb0ee7555009cda926d7341eece2045f#body_text
is schema:about of	named entity 'biopsies' named entity 'era' named entity 'OF PROSTATE CANCER' named entity 'PART OF' named entity 'OBJECTIVE' named entity 'CRISIS' named entity 'patients' named entity 'prostate' named entity 'MRI' named entity 'prostate biopsies' named entity 'continuous variable' named entity 'biopsy' named entity 'lesion' named entity 'prostatectomy' named entity 'logistic regression' named entity 'prostate cancer' named entity 'ISUP' named entity 'lesion' named entity 'prostatectomy' named entity 'PSA' named entity 'surgical procedure' named entity 'PSA' named entity 'continuous variable' named entity 'Austria' named entity 'biopsies' named entity 'biopsy' named entity 'infection' named entity 'biopsy' named entity 'clinical characteristics' named entity 'biochemical recurrence' named entity 'PI-RADS' named entity 'tertiary referral center' named entity 'biopsies' named entity 'PI-RADS' named entity 'biopsy' named entity 'biopsies' named entity 'intensive care unit' named entity 'PI-RADS' named entity 'randomized trials' named entity 'MRI' named entity 'biopsy' named entity 'diffusion-weighted' named entity 'biopsies' named entity 'PI-RADS' named entity 'biopsy' named entity 'antibiotic prophylaxis' named entity 'biopsies' named entity 'biopsy' named entity 'biopsy' named entity 'prostate cancer' named entity 'TRUS' named entity 'prostate cancer' named entity 'biopsies' named entity 'prostate cancer' named entity 'biopsy' named entity 'intensive care' named entity 'biopsies' named entity 'PSA level' named entity 'biopsies' named entity 'biopsies' named entity 'radical prostatectomy' named entity 'biopsy' named entity 'biopsy' named entity 'biopsy' named entity 'COVID-19 pandemic' named entity 'linear regression' named entity 'genitourinary' named entity 'prostatectomy' named entity 'tumor' named entity 'clinically significant' named entity 'biopsies' named entity 'PSA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software